Ruth Palmer Lab
Ruth Palmer Lab
News
People
Events
Publications
Contact
Funding
Ganesh Umapathy
Latest
The Alk receptor tyrosine kinase regulates Sparkly, a novel activity regulating neuropeptide precursor in the Drosophila central nervous system
Comparison of (177)Lu-octreotate and (177)Lu-octreotide for treatment in human neuroblastoma-bearing mice
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
In vivo Profiling of the Alk Proximitome in the Developing Drosophila Brain
Mapping the Phospho-dependent ALK Interactome to Identify Novel Components in ALK Signaling
ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation
Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGalpha) in neuroblastoma patient samples with chromosome arm 2p rearrangements
Targeting anaplastic lymphoma kinase in neuroblastoma
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Cite
×